Sean Bohen (file photo)
November 1, 2020 03:08 PM ESTUpdated November 3, 11:07 AM
People
Financing
Bioregnum
Opinion

Sean Bo­hen just wrote the hand­book on how to make a quick for­tune in biotech

If you ask any­one in drug de­vel­op­ment about what mo­ti­vates them — or even if you don’t — you’re go­ing to get a reg­u­lar dou­ble-bar­reled blast about …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

Up­dat­ed: FDA ad­comm splits votes on Genen­tech and J&J can­cer drugs

RFK Jr. spars with sen­a­tors over re­search cuts, HHS bud­get plan

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times